Luke Walker

Luke Walker

Company: Seagen

Job title: Vice President – Clinical Development


Dr. Walker is a medical oncologist who received his medical degree from the University of Oklahoma, followed by training in internal medicine, hematology/oncology, and hematopoietic stem cell transplant at Oregon Health Sciences University. After practicing for several years in Seattle as a hematologist/oncologist, including directing a multidisciplinary Thoracic Oncology Clinic and Anticoagulation Clinic, he has been working in drug development since 2011, including stints at Oncothyreon, Cascadian Therapeutics, and now Seattle Genetics. He has been involved in the clinical development of tucatinib since 2013, and now serves as the Global Development lead for TUKYSA and Vice President of Clinical Development at Seattle Genetics.


Live Presenter Q&A 10:20 am

Read more

day: Day Two

The Use of Highly Selective TKIs for HER2+ CNS Metastases- Tucatinib in Combination With Capecitabine & Trastuzumab 9:20 am

• Expanding clinical trials to include patients with active brain metastases • Exploration of the use of dual HER2 inhibition • Understanding the complexity of clinical endpoints for measuring activity of therapeutics against brain metastasesRead more

day: Day Two

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.